Navigation Links
OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
Date:6/24/2009

BOTHELL, WA, and VANCOUVER, June 24 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company has reached an agreement with the U.S. Food and Drug Administration (FDA) via the special protocol assessment process (SPA) on an amendment to the design of a Phase 3 registration trial of OGX-011, its lead product candidate targeting castrate resistant prostate cancer (CRPC). The FDA has agreed on modifications to the study population of a previously reviewed Phase 3 trial featuring survival as the primary endpoint. The study population has been modified to evaluate patients receiving first-line chemotherapy, rather than those receiving second-line chemotherapy. FDA agreed that the amended protocol adequately addresses the objectives necessary to support a regulatory submission.

"We are now ready to proceed with two Phase 3 trial designs from the FDA via the SPA process, one in first-line and one in second-line treatment of advanced prostate cancer," said Scott Cormack, President and CEO of OncoGenex Pharmaceuticals. "The trial for first-line treatment evaluates overall survival benefit for OGX-011 while the trial for second-line treatment evaluates for a durable pain palliation benefit. Based on the robustness of the OGX-011 survival benefit observed in the randomized Phase 2 trial for first-line docetaxel treatment, we felt evaluating both of these patient populations, as well as both endpoints, in our Phase 3 trials better positions the availability of OGX-011 treatment to a larger number of men with prostate cancer."

The Phase 3 trial has been designed in collaboration with internationally recognized experts in the treatment of patients with castrate resistant prostate cancer (CRPC) including Dr. Celestia Higano at the University of Washington and Dr. Kim Chi at the University of British Co
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
3. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
4. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
5. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
6. OncoGenex Reports First Quarter Financial Results
7. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
8. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
9. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
10. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
11. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)...   JOLT , a leading technology accelerator, announced today ... portfolio of startups. Next-level tech and boundary-pushing innovation have ... accelerator, and Cohort four is no exception, with six ... its launch in July 2012, JOLT has produced 17 ... at 23 investments, JOLT,s portfolio has an overall mix ...
(Date:7/28/2014)... --  Propeller Health , the FDA-cleared digital health solution ... Brad Towle as Senior Vice President, Business and ... company,s sales growth, customer acquisition and program expansion. ... past role in the development of accountable care organizations, ... time in the industry," said David Van Sickle ...
(Date:7/28/2014)... July 28, 2014  InterMune, Inc. (NASDAQ: ... second quarter 2014 financial results at the close of ... conference call and webcast will be hosted by InterMune ... Interested investors and others may participate in the ... (international), conference ID#21728775. A replay of the webcast and teleconference ...
(Date:7/26/2014)... Albany, NY (PRWEB) July 26, 2014 ... 2020 provides key market data on the Canada ... in millions of US dollars, volume (in units) ... segments - High-End Endoscopy Visualization Systems, Mid-Range Endoscopy ... Browse Full Report at http://www.marketresearchreports.biz/analysis/213254 . , ...
Breaking Biology Technology:JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2InterMune to Release Second Quarter Financial Results on August 6 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5
... Without effective and proper networking techniques, you may not be ... to other professionals. While people have their own networking style ... , ,You need to do what works best for you ... to learn new ideas about networking from other professionals who ...
... Neurognostics , a home-grown Milwaukee medical device company, finished ... first to take advantage of Wisconsin's new tax credits for ... an investment. , ,Neurognostics oversubscribed on its $1 million angel ... af Neurognostics. As a tech-based research and development company, the ...
... project to match genetic information from Alzheimer's patients with ... ,The two-year project is the first to tap the ... for its Personalized Medicine Research Project, one of the ... of electronic medical records, the project aims to develop ...
Cached Biology Technology:Improve your networking skills by learning from other professionals 2Improve your networking skills by learning from other professionals 3Improve your networking skills by learning from other professionals 4Milwaukee firm among first to use Act 255 tax credits in investor pitch 2Milwaukee firm among first to use Act 255 tax credits in investor pitch 3Milwaukee firm among first to use Act 255 tax credits in investor pitch 4Marshfield study mixes DNA into electronic medical record to screen for Alzheimer's 2Marshfield study mixes DNA into electronic medical record to screen for Alzheimer's 3
(Date:7/28/2014)... He calls himself the bug hunter, but the target ... be found and identified with special methods and instruments. ... State Veterinary Diagnostic Laboratory at Kansas State University, recently ... enterovirus G, which is an important find in the ... cells, but didn,t know what it was," Hause said. ...
(Date:7/28/2014)... July 28, 2014 Research and Markets ... Market in Latin America 2014-2018" report to their ... Biometrics measure and analyze biological data. These systems ... eye retinas, voice patterns, and hand measurements from the ... stored templates. The main purpose of a biometrics system ...
(Date:7/28/2014)... became the first man to reach the South Pole ... an international team of scientists led by Joe McConnell ... air pollution from industrial activities arrived long before. , ... spaced locations around the Antarctic continent, including the South ... reconstruction to date of lead pollution over the Earth,s ...
Breaking Biology News(10 mins):Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3Biometrics Market in Latin America 2014-2018 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3
... used as weapons is truly dreadful, but there is plenty ... ancient times. * Bioterrorism, as it is dubbed, ... a safer place against a myriad of old scourges both ... to uncork a nasty cloud of germs. The ...
... oven technology that most people use to heat up leftover ... industry, providing a new way to make thin-film photovoltaic products ... Oregon State University have for the first time developed a ... zinc tin sulfide, a promising solar cell compound that is ...
... many mutations from their fathers as from their mothers, and ... mother,s, researchers have found in the largest study of human ... DNA of around 85,000 Icelanders, also calculates the rate of ... ancestors diverged from nonhuman primates. It is one of two ...
Cached Biology News:Boston subway system to be used to test new sensors for biological agents 2Microwave ovens may help produce lower cost solar energy technology 2Most mutations come from dad 2Most mutations come from dad 3
Ultra-sensitive, non-radioactive detection of Protein G. Measure Protein G levels quickly and easily....
Request Info...
TRIS-EDTA based buffer prepared from RNase-free water suitable for storage and dilution of siRNA, pH 8, store at 4 C ...
Request Info...
Biology Products: